InfuSystem Holdings, Inc. (INFU) provides infusion pumps and related biomedical services for hospitals, oncology clinics, and home-based care across the United States and Canada. Three verifiable, current analyst price targets were reviewed to establish the central target: Roth MKM at $15.00 (raised from $14.00 in February 2026), Lake Street's Ben Haynor at $17.50 (reiterated in September 2026), and B. Riley Securities at $20.00 (raised from $12.00 in August 2026). The arithmetic mean of these three figures is $17.50, with a low-to-high range of $15.00 to $20.00.
All three analysts carry Buy ratings, and independent trackers from S&P Global and MarketBeat describe the aggregate as a Strong Buy. The spread between $15 and $20 is meaningful for a stock trading near $14.68, and it signals genuine divergence in how analysts value the company's growth trajectory rather than uniform conviction about the exact target. The $17.50 figure used here is a calculated average, not an officially published consensus figure.
At a recent price of about $14.68, INFU trades just below its 52-week high of roughly $14.85. Reaching $17.50 implies about a 19% gain, which is a substantial move that would require the stock to break decisively into new all-time-high territory and hold there.
The path toward the target would most plausibly be driven by continued revenue expansion and margin improvement. Trailing twelve-month revenue is approximately $144 million, with diluted EPS (earnings per share) of about $0.44 and a trailing P/E (price-to-earnings) ratio in the low 30s. Analysts model full-year 2026 EPS near $0.46, rising toward roughly $0.57 for 2027. If earnings keep growing while the company demonstrates durable demand in its higher-margin service lines, the valuation could support a higher stock price over time.
Several factors could support the shares. The company has posted a pattern of earnings beats in recent quarters, and the consensus rating of Strong Buy reflects analyst confidence in the story. Growth in outsourced biomedical services and direct-to-patient home infusion aligns with a broader healthcare shift toward cost-effective, site-of-care flexibility. Rising gross margins and improving free cash flow give the business room to self-fund expansion. A supportive technical backdrop—shares up more than 60% year to date and near a 52-week high—indicates positive investor sentiment and momentum.
Several risks could stand in the way. At a trailing P/E in the low 30s, the stock already prices in meaningful growth, leaving less room for error if results disappoint. As a small-cap with a market value near $294 million, the shares are prone to sharp swings on modest news or single-client developments. The business depends on a relatively concentrated set of healthcare provider and supplier relationships, so the loss of a significant account could weigh on results. Slower adoption of home infusion programs, reimbursement changes, or broader sector rotation away from healthcare could also compress the multiple.
The most relevant technical level is the 52-week high near $14.85, which now functions as near-term resistance. A sustained move above that zone would put the stock into record territory and could open the path toward the $17.50 target. On the downside, the stock's roughly 52-week low of $7.29 and the psychological $10 level mark the broad trading range from which the shares have climbed. Because the stock has rallied sharply, support has also shifted higher; the area around $13–$13.70, where the stock consolidated before its recent advance, is a key zone to watch for any pullback.
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms can differ, and no single timeline is guaranteed. Investors tracking progress toward $17.50 should watch quarterly earnings and guidance, gross margin trends, and any updates on new or expanded provider contracts. Revisions to analyst estimates and price targets—particularly whether the $15 and $20 views converge—will also matter. Broader healthcare reimbursement news and any shift in small-cap or healthcare-sector sentiment are worth monitoring alongside company-specific results.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For traders following a stock like INFU, this tool can help identify opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review. Consider exploring the signals to complement your own research and stay ahead of changing market dynamics.
The $17.50 central target is a calculated average of three analyst price targets spanning $15 to $20, and it sits roughly 19% above the latest price near $14.68. Reaching it would require the stock to break into record territory on continued earnings growth and sustained demand in its infusion and oncology service lines. Support comes from a Strong Buy consensus, improving margins, and strong recent momentum, while the principal obstacles are a demanding valuation, small-cap volatility, and customer concentration. The wide analyst range underscores genuine uncertainty about the pace of growth, so investors should monitor earnings, guidance, and estimate revisions rather than treat $17.50 as a certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, INFU has been loosely correlated with AMIX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then AMIX could also see price increases.
| Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
|---|---|---|---|---|
| INFU | 100% | +2.06% | ||
| AMIX - INFU | 44% Loosely correlated | -14.32% | ||
| VREX - INFU | 42% Loosely correlated | -0.22% | ||
| ICUI - INFU | 39% Loosely correlated | -1.84% | ||
| BFLY - INFU | 35% Loosely correlated | -7.69% | ||
| INSP - INFU | 35% Loosely correlated | -2.10% | ||
More | ||||
| Ticker / NAME | Correlation To INFU | 1D Price Change % |
|---|---|---|
| INFU | 100% | +2.06% |
| Health Services category (238 stocks) | -5% Poorly correlated | -2.69% |
| Medical/Nursing Services category (138 stocks) | -5% Poorly correlated | -3.38% |